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Summary 
Eicosanoids play an integral part in homeostatic mechanisms related to skin health and 
structural integrity. They also mediate inflammatory events developed in response to 
environmental factors, such as exposure to ultraviolet radiation, and inflammatory and 
allergic disorders, including psoriasis and atopic dermatitis. This review article discusses 
biochemical aspects related to cutaneous eicosanoid metabolism, the contribution of these 
potent autacoids to skin inflammation and related conditions, and considers the importance of 
nutritional supplementation with bioactives such as omega-3 and omega-6 polyunsaturated 
fatty acids and plant-derived antioxidants as means of addressing skin health issues.  
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1. Introduction 
Eicosanoids are produced by all cutaneous cell types and contribute to homeostatic processes 
and inflammatory responses associated with injury, allergy and other acute or chronic 
conditions [1-3]. Membrane phospholipid-esterified arachidonic acid (20:4n-6; AA) and the 
C20 polyunsaturated fatty acids (PUFA) dihomogamma-linolenic acid (DGLA; 20:3n-6) and 
eicosapentaenoic acid (EPA; 20:5n-3) are mobilised by phospholipases and serve as 
precursors to various eicosanoids that are formed by cutaneous cyclooxygenase (COX) and 
terminal prostanoid synthases (PGS),  lipoxygenase (LOX) and cytochrome P450 (CYP) 
enzymes. Eicosanoid-like molecules are also produced through non-enzymatic oxidations, 
whilst other n-6 and n-3 PUFA including linoleic acid (LA; 18:2n-6) and docosahexaenoic 
acid (DHA; 22:6n-3) can give rise to analogous lipid mediators [4, 5] (Figure 1).  
 Skin is considered the largest organs of the body and constitutes a physical barrier 
protecting it from injury, infection, water and electrolyte loss, as well as being an important 
player of the immune system [6]. It has a multilayered structure that supports the formation of 
a highly-keratinized outer epidermal permeability barrier, whilst the epidermis and dermis 
host a number of primary cells including epidermal keratinocytes, melanocytes, and 
Langerhans cells, as well as dermal fibroblasts, mast cells, and infiltrating leukocytes. 
Inflammation partakes in physiological mechanisms mediating skin healing and repair post 
injury, whilst it is a central feature in a number of dermatoses and underpins cancer 
development. Skin cells participating in these events produce eicosanoids in response to 
various stimuli and this can be influenced by dietary manipulation; therefore an in depth 
appreciation of these potent lipid mediators of cutaneous inflammation is of great importance.  
 This article aims to review our current understanding of cutaneous eicosanoid 
production and their contribution to inflammatory conditions, and will discuss systemic and 
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local interventions that have been considered as means of manipulating lipid mediator 
production with a view to improve skin health and develop chemopreventive regimes.  
 
2. Cutaneous Eicosanoid Biology  
Fatty acids are crucial for skin structure and function, as shown by the seminal studies of 
Burr et al [7] that demonstrated its dependence on systemically provided essential fatty acids.  
LA constitutes approximately 12% of cutaneous fatty acids and is pivotal for the integrity of 
the epidermal barrier [8-10]. Furthermore, epidermal keratinocytes are characterized by lack 
of ∆5 and ∆6 desaturase activity [11] and rely on systemic provision of long chain PUFA 
such as AA, DHA and EPA that, collectively, account for no more than 5% of total fatty 
acids [12]. Although their precursors are found at such low levels, PUFA-derived prostanoids 
and hydroxy-fatty acids are important for skin physiology and homeostasis [9, 13, 14].   
2.1. Phospholipases 
Phospholipase A2 (PLA2) is the principle lipolytic enzyme providing AA and other PUFA for 
eicosanoid biosynthesis [15]. Of the many isoforms, the cytosolic PLA2 (cPLA2) is 
considered the main enzyme mediating the release of AA for cutaneous eicosanoids with its 
activity and expression found induced in conditions characterized by oxidative stress (e.g. 
sunburn) [16]. The secretory PLA2 (sPLA2) has also been found in keratinocytes and sites of 
cutaneous inflammation (e.g. psoriasis) [17, 18]. Finally, phosphatidylinositol (PI)- specific 
phospholipase C (PLC) that releases diacylglycerol (DAG) which can be further metabolised 
by lipases to generate AA and in this way potentially contribute to skin eicosanoids, has also 
been reported to be involved in certain inflammatory conditions (e.g. psoriasis) [19, 20]. 
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2.2. Cyclooxygenase-derived mediators 
Cyclooxygenase isoforms, i.e. the constitutive COX-1 and inducible COX-2,  convert AA to 
the unstable intermediate PGH2 that is further isomerized to prostaglandins, prostacylin or 
thromboxanes (prostanoids) depending on the prevalence of the corresponding terminal 
prostanoid syntases. EPA and DGLA are also metabolized by COX and generate  a range of 
prostanoids (Figure 1). Most mammalian cutaneous cells express COX-1 and -2, and studies 
on human and animal skin have shown the production of PGE2, PGE1, PGE3, PGD2, PGF2α, 
PGI2, and TXB2 [13, 21, 22]. However, the exact prostanoid profile for each skin cell type, 
and the influence these mediators may have on transcellular metabolism and the overall skin 
function continues to be of interest.  
 PGE2 is one of the main cutaneous eicosanoids produced by both epidermal 
keratinocytes and dermal fibroblasts. It exhibits potent pro-inflammatory and vasodilatory 
properties, promotes proliferation and modulates immunosuppression [22, 23]. These effects 
are mediated through G-protein coupled receptors EP1-4 expressed in all primary skin cells 
[24-27]. PGE2 is formed via the cytosolic and microsomal PGE synthases (cPGES, mPGES-1 
and mPGES-2) [28]. Interestingly, there is evident for linked expression of the inducible 
mPGES-1 and COX-2 isozymes demonstrating in skin cells the presence of an efficient 
system for increased PGE2 production upon stimulation [29]. Furthermore, PGE2 is involved 
in keratinocyte proliferation and differentiation, and this has direct consequences for the 
epidermal barrier function [25, 30, 31]. It has also been suggested that fibroblast-produced 
PGE2 influences keratinocyte growth showing the cross-talk and biochemical support 
between skin layers [32, 33]. Finally, PGE2 can act as keratinocyte chemoattractant and 
modulator of dermal fibroblasts, and in this way can facilitate wound healing [34, 35].  
Recent reports suggest that epidermal melanocytes can also produce PGE2 although the lack 
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of COX-2 protein expression in these cells may explain the relatively low levels observed 
[36, 37]. However, PGE2 has a direct effect on melanocyte-mediated post-inflammatory 
pigmentary responses and melanocyte dendricity showing relevance to skin tanning [27, 38].  
 Langerhans cells and dermal mast cells are considered to be the principle producers of 
cutaneous PGD2, a potent anti-proliferative and anti-inflammatory prostaglandin involved in 
immune and allergic responses [23, 39]. It exhibits its effects through the CRTH2 and DP 
receptors expressed in various skin cells, including keratinocytes [40, 41]. Recent studies 
have shown the production of PGD2 by epidermal melanocytes [37]. Notably, Langerhans 
cells and mast cells express the hematopoietic PGD synthase (H-PGDS) isoform that 
responds to antigen stimulation [42], whilst melanocytes express the lipocalin PDGS (L-
PGDS) isoform [37, 43] reflecting their neural crest origin. PGD2 is precursor to the anti-
inflammatory cyclopentanone prostaglandins PGJ2, ∆12-PGJ2 and 15d-PGJ2 that are formed 
through non-enzymatic hydrolysis [44]. Although ∆12-PGJ2 has been shown to exhibit anti-
proliferative effects in epidermal cells in vitro [45], the formation of such potent electrophiles 
by skin cells has not yet been well documented.  
 PGF2α can be produced by the PGH2 9,11-endoperoxide reductase or from PGE2 via  
9-ketoreductase, whilst the epimeric form 9α,11β-PGF2 (11-epi-PGF2α) is formed from PGD2 
via 11-ketoreductase [46]. PGF2α has been found in whole skin and keratinocytes in culture 
[21, 22, 47] and has been linked to inflammation, immune responses, pigmentation and hair 
growth [27, 38, 48]. The effects of PGF2α are mediated through the FP receptor found 
expressed in epidermal cells and melanocytes [49-51]. Finally, prostacyclin (PGI2; detected 
as 6-keto-PGF1α) and TXA2 (detected as TXB2) have been found in whole skin extracts and 
cultured cells in vitro, albeit at low concentrations and it is possible that they may also be 
products of vascular endothelial cell or derive from infiltrating leukocytes [21, 31]. IP and TP 
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receptors have been identified in keratinocytes and other skin cells [24, 52] and their 
prevalence has been linked to PGI2 and TXA2 signalling events accompanied cutaneous 
inflammatory and immune disorders [53, 54].  
 Cutaneous prostaglandins are catabolised through oxidation via the NAD+-dependend 
15-ketoprostaglandin dehydrogenases (15-PGDH) followed by reduction through the ∆13-15-
ketoprostaglandin reductases [55]. The resulting 15-keto- and 13,14-dihydro15-keto 
prostaglandins have substantially reduced biological activities. The enzymes and products of 
prostaglandin catabolism are ubiquitously found in human and animal cells [22, 56, 57]. 
2.3. Lipoxygenase-derived mediators 
 Lipoxygenase (LOX) activities are conventionally defined by their positional 
selectivity when oxygenating AA in a stereoselective manner [5, 58], although this 
classification system does not always reflect the isozyme complexity as suggested by 
phylogenetic studies [59]. Human and animal skin expresses 5-, 8-, 12- and 15-LOX 
activities producing an array of hydroxy-fatty acid derivatives of AA, LA, DGLA, EPA and 
DHA, including 12-HETE, 15-HETE, 13-HODE and 15-HETrE [22, 60-63].  
 5-LOX is activated by FLAP (5-lipoxygenase activating protein) to produce the 
unstable peroxide 5-hydroperoxy eicosatetraenoic acid (HPETE) from AA, that is quickly 
reduced to 5-eicosatetraenoic (HETE) acid and 5-oxo-eicosatetraenoic (ETE) acid [64], or 
dehydrated to leukotriene (LT) A4, precursor to LTB4. LTA4 can be further conjugated to 
GSH and generate a series of peptido-leukotrienes, or, following transcelluar metabolism, 
contribute to the formation of lipoxins (LX) [65]. Cutaneous 5-LOX activity is rather low and 
has been associated mainly with epidermal keratinocytes [66, 67], Langerhans cells [68, 69] 
and infiltrating leukocytes [65]. Interestingly, 5-LOX activity is increased when keratinocytes 
differentiate [70]. LT and 5-oxo-ETE are potent chemoattractants [64, 71] that can contribute 
7 
 
to cutaneous inflammation and allergy [72, 73], however, the actual formation of 
peptidoleukotrienes in human skin has been disputed [74].  
 12-LOX activity is mediated by the highly abundant cytosolic leukocyte-type 12-
LOX, the microsomal platelet-type 12-LOX, and the unique to mammalian skin cells, 12R-
LOX  [75]. The epidermis-type lipoxygenase-3 (eLOX-3) is acting in sequence with 12R-
LOX contributing to the terminal differentiation of keratinocytes and integrity of the 
epidermal barrier [76, 77]. 15-LOX activity is attributed to two isoforms: the reticulocyte-
type 15-LOX-1 and epidermis-type 15-LOX-2. Interestingly, leukocyte-type 12-LOX can 
form both 12- and 15-HETE and has high homology to 15-LOX-1; therefore, these isozymes 
are frequently referred to as 12/15-LOX [59]. Finally, murine epidermis is expressing 8-
LOX, a homologue of the inducible 15-LOX-2, that has not yet been found in human skin 
[78, 79]. 
 12-HETE is a potent pro-inflammatory chemottactic  mediator, produced by 
epidermal keratinocytes and dermal fibroblasts. The expression of 12-HETE binding sites in 
keratinocytes and Langerhans cells suggesting an active involvement in cutaneous wound 
healing and inflammatory disease [35]. It has also been suggested that dermal 15-HETE can 
inhibit epidermal 12-LOX activity [80], whilst the reciprocal regulation of 12-LOX and 15-
LOX activities has been reported in human keratinocytes in vitro [81]. Furthermore, 15-
HETE may dampen the infiltration of PMN and exercise further anti-inflammatory activities 
as biochemical precursor of lipoxins [65]. 15-LOX and its metabolites may also mediate anti-
cancer and protective effects similarly to its homologous murine 8-LOX [82]. Anti-
inflammatory and anti-proliferative activities have also been attributed to 13-HODE and 15-
HETrE, 15-LOX-derived mediators of LA and DGLA respectively, that have also been found 
in human and animal skin [62, 83, 84]. Finally, 8, 9- and 11-HETE have also been detected in 
human skin, although their exact origin has not yet been fully elucidated [22, 62].  
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2.4. CYP-derived mediators 
Skin cells express a number of CYP isoforms involved in drug and  xenobiotic metabolism 
and production of omega-hydroxylated ceramides for the epidermal barrier [85]. Although 
some AA-specific mono-oxygenases have been identified in epidermal keratinocytes [86, 87], 
the overall contribution of CYP in cutaneous eicosanoid production remains to be explored.  
CYP-derived eicosanoids include cis-epoxyeicosatrienoic acids (EET), involved in vascular 
relaxation and angiogenesis, their biologically inactive dihydro- metabolites (DHET), various 
mid-chain HETE (e.g. 8-,9-11-,12-15-HETE), and ω-hydroxylated PUFA such as 20-HETE 
(reviewed in [5]). Furthermore, CYP isoforms express varied stero- and regio-selectivity 
resulting in the formation of multiple AA mediators, including R-HETE species. It is 
therefore plausible that some of the HETE identified in the skin and cutaneous cells in vitro 
may be products of CYP-mediated reactions. EET have been identified in mouse skin cells 
[88] and 11,12- and 14,15-EET have been shown to play a part in the cornification of human 
and mouse keratinocytes [89].   
2.5. Non-enzymatically produced eicosanoids 
Free-radical induced lipid peroxidation can generate isoprostanes or racemic mixtures of 
hydroxy fatty acids [90]. The main feature of these reactions is the lack of stereoselectivity 
and the resulting products are regio- and stereo-isomers of their enzymatically-produced 
counterparts. Oxidative stress is a feature of many cutaneous conditions and the formation of 
isoprostanes has been reported in sunburn skin whilst racemic hydroxy-fatty acids have been 
identified in psoriactic skin [91, 92]. Therefore, elucidating the exact stereochemistry of the 
mediators involved in each case is needed in order to appreciate the origin and bioactivity of 
cutaneous eicosanoids.      
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3.  Eicosanoids in cutaneous inflammatory diseases  
Inflammation is a prominent feature in an number of acute and chronic skin diseases 
including psoriasis and atopic dermatitis, disorders arising from exposure to UVR radiation 
(sunlight or recreational use of sunbeds), as well as being an underpinning factor in skin 
cancer. Cutaneous eicosanoids have been shown to be are actively engaged in many 
biochemical and cellular events involved in these conditions.  
3.1. Psoriasis 
Psoriasis is a relatively common chronic inflammatory and proliferative skin disease, with 
genetic and environmental aetiologies, that is characterized by abnormalities in skin lipids 
and increased production of inflammatory mediators [93, 94].  
 Studies have shown increased sPLA2, cPLA2 and PLC activities in psoriatic skin [17-
19, 95]. 12-HETE is the predominant eicosanoid found greatly up-regulated in psoriasis, 
whilst increases in the levels of PGE2 and PGF2α are less prominent [3, 96] and  15-HETE is 
decreased in uninvolved psoriatic skin compared to healthy epidermis [97]. Chiral analysis 
has revealed the prevalence of 12R-HETE in psoriatic scales pointing at the involvement of 
12R-LOX [75]. 13-(R,S)-HODE have also been found in psoriatic skin [98] suggesting not 
only an upregulation of LOX reactions but also the potential formation of racemic hydroxy-
fatty acid mixtures due to oxidative stress, another feature of this disease [99]. Furthermore, 
the contribution of R-hydroxy-fatty acid producing CYP isoforms, cannot be excluded. CYP 
isozymes can mediate the oxidation of eicosanoids, as suggested by the co-localisation of 
COX-2, mPGES-1 and CYP4F8  in psoriatic lesions leading to oxidation of PGE2 [100]. In 
the past there has been a strong interest in the role of 5-LOX-derived leukotrienes in psoriasis 
and other skin disorders [96, 101]. However, the low 5-LOX activity in epidermal 
keratinocytes indicates that these eicosanoids may be formed through transcellular pathways 
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involving dermally infiltrating neutrophils [102], a consequence of the high concentration of 
the 12-HETE, a potent chemotactic eicosanoid highly prevalent in psoriatic skin.  
 The eicosanoid pathway has also been of interest in developing therapeutic 
approaches for psoriasis. 15-HETE has shown potential as an anti-inflammatory agent, as 
supported by the improvement observed in a clinical study following its injection on psoriatic 
scales [103]. These properties of 15-HETE can be attributed to its ability to counteract the 
chemottactic potencies of 12-HETE and LTB4 [80, 104], as well as acting as substrate for the 
formation of lipoxins through transcellular metabolism involving the neutrophil inflitrate 
[65]. Nutritional approaches with GLA, DGLA and EPA, as well as local application and 
intravenous administration of EPA have also been considered, aiming to reduce the 
prevalence of AA-derived HETE and increase the concentration of less inflammatory PUFA 
derivatives such as 15-HEPE and 15-HETrE [105-108]. Finally, there has been interest in 
developing specific 12-LOX and PLA2 inhibitors as therapeutic agents for psoriasis [109, 
110]. 
3.2. Atopic Dermatitis  
Atopic dermatitis is a common chronic allergic inflammatory disease [111]. It is attributed to 
genetic and environmental factors, and is characterized by abnormal skin barrier formation; 
however, the exact aetiology of it is not clear [112]. Epidermal keratinocytes are considered 
actively involved in atopic and allergic contact dermatitis, both in terms of producing 
inflammatory mediators but also in their ability to respond to inflammatory and allergenic 
stimuli [113]. 
 As in most cutaneous inflammatory conditions, atopic dermatitis is characterised by 
increased PLA2 activity [114] with COX-derived prostanoids apparently more involved than 
LOX-derived mediators [115]; a similar profile also observed in contact dermatitis [26]. 
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Although the involvement of 5-LOX and LTB4 has been shown in animal models of atopic 
dermatitis [116], as discussed, it is likely that this can be attributed to dermal neutrophilic 
infiltrates. PGD2 is one of the principle prostanoids involved in atopic dermatitis because of 
its immunomodulatory properties and the active role of Langerhans cells and mast cells (the 
main cutaneous courses of PGD2) in this primarily immunological problem [21, 117]. Finally, 
the vasoactive PGI2 and immunosuppressive PGE2 have also been suggested to be actively 
involved [26, 53]. In vitro studies with GLA and DHA suggest that PUFA can alter the 
profile of eicosanoids produced by cutaneous immune cells and, in this way, improve atopic 
dermatitis [118]. 
3.3. Sunburn Response 
Inflammation plays a central role in the development of sunburn, a cutaneous reaction to 
acute exposure to sunlight with eicosanoids involved in associated biochemical and cellular 
events [1]. Inflammation is also involved in other UVR-related cutaneous conditions 
including photosensitivity disorders, photoageing, and skin cancer [119-121]. 
 Overall, sunburn is characterised by increased COX- and LOX-mediated eicosanoid 
production. Exposure of cells to UVR (primarily UVB 290-320nm but also UVA 320-
400nm) generates reactive oxygen species and activates signalling cascades, transcription 
factors and gene expression [122]. UVR-induced oxidative stress stimulates the activity and 
expression of cPLA2 in human and animal skin, and keratinocytes in vitro [16, 123]; UVR-
mediated activation of PLC has also been reported [124]. Up-regulation of COX-2 occurs 
within 3-4 hours post UVR and results in increased production of PGE2 and PGF2α [22], 
whilst the observed reduction in PGD2 levels has been attributed to migration of epidermal 
Langerhan cells [125]. Studies in animals skin cells suggest UVR-induced up-regulation of 
prostaglandin synthase and receptor mRNA expression [24], and the catabolism of 
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prostanoids may be temporarily reduced, as shown by studies reporting reduction in 15-
PGDH mRNA and protein post UVR [126].  The expression of cutaneous 12-LOX and 15-
LOX is also up-regulated following exposure to UVR with concomitant production of a range 
of mediators, including 8-, 9-, 11- 12- and 15-HETE, and 13-HODE [22, 62]. Not much is 
known about the effect of UVR on eicosanoid production by CYP, although a UVR-related 
effect should be anticipated as alluded to by report showing increased activity of a cutaneous 
CYP isoform involved in lipid metabolism [127].  
 The role of eicosanoids in sunburn is multifaceted. PGE2 can mediate the initial 
inflammatory phase but later on it can play a part in the resolution of inflammation and tissue 
repair [128]; furthermore, continuous production of PGE2 in unresolved inflammation may 
contribute to the immune suppression observed in photocarcinogenesis [120]. 12-HETE is a 
potent leukocyte chemoattract but can also be involved in keratinocyte and fibroblast 
mediated healing events [31, 35], whilst 15-HETE and 13-HODE may assist in restricting 
pro-inflammatory signals [65, 83].  
 
4. Effect of PUFA and antioxidants in cutaneous inflammation  
The active involvement of fatty acids in skin health and epidermal barrier function justifies 
the choice of systemic supplementation with n-3PUFA as an effective strategy for the 
improvement of inflammatory conditions [129]. Long chain n-3PUFA effect eicosanoid 
production through their ability to offer alternative substrates to lipid metabolizing enzymes 
and through their role in cell signalling, gene expression and, consequently, enzyme protein 
levels [130]. Generally, COX-mediators of n-3PUFA, such the EPA product PGE3, are 
considered less inflammatory and 12-LOX products, such 12-HEPE, less potent 
chemoattractants than their AA-counterparts. However, it is also possible that the formation 
13 
 
of these mediators reduces the effective concentration of AA-eicosanoids resulting in a less 
inflammatory environment. Furthermore, EPA inhibits COX-2 expression in many cell types, 
although there is some evidence that this may not be the case in human keratinocytes [131] 
suggesting the need to further elucidate the response of epidermal and dermal cells.   
 Human skin responds to nutritional intervention and studies with fish oil n-3PUFA 
have shown reduced erythema and decreased levels of PGE2 following UVR treatment [132]. 
This finding points towards a possible chemopreventive strategy to address the harmful 
effects of solar radiation. The role of n-3PUFA-derived meditators has also been considered 
in wound healing where the profile of lipid chemoattractants can influence the leukocytic 
infliltrate and degree of epithelization [133-135]. Finally, as discussed, dietary interventions 
with n-3PUFA have shown amelioration in psoriasis and atopic dermatitis, strengthening the 
evidence for the beneficial role of n-3PUFA in cutaneous health [106, 118]. 
 Finally, the role of oxidative stress in many aspects of cutaneous biology has raised 
interest in systemic or topical  use of antioxidants as potential modulators of skin health, with 
a number of natural products being assessed for their ability to exert such protective effects. 
Plant polyphenols exhibit potent antioxidant properties and, when tested in animal models or 
cells in vitro, have shown potent beneficial effects related to inflammation,  photoprotection,  
immunomodulation [136, 137]. Green tea and cocoa bean catechins are very promising 
bioactives for skin health with aspects of their bioactivities are mediated through interactions 
with cutaneous eicosanoids as shown by reports on the reduction of UVR-induced erythyma 
and COX2- activity in mice, reduction of COX-2, EP2 and EP4 expression, and inhibition of 
COX and LOX-products [138, 139]. However, placebo-controlled clinical studies are needed 
in order to evaluate their effect in skin inflammation and substantiate any relevant claims. 
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5. Concluding remarks 
Skin is not only the biggest organ of the body but it is immediately visible so that any health 
issues affecting its appearance raise concern. Inflammation can be part of  physiological 
shelf-regulated responses or underpin the pathology of cutaneous diseases; therefore a 
detailed understanding of the mediators involved in each case can be valuable in directing the 
effort for new therapeutics. Lipidomic approaches, supported by recent developments in lipid 
analysis, have not only made possible the identification of novel bioactive lipids, but have 
offered detailed insight to the complexity of mediators involved in the various phases of 
inflammation. For example, when applied to sunburn skin, lipidomics showed the 
contribution of more lipid species that previously thought, and has raised questions about 
their role [22]. Nutritional supplementation with PUFA alters the pool of fatty acids available 
for eicosanoid biosynthesis, manipulates the profile of known mediators and permits 
formation of new species, such as EPA and DHA-derived resolvins and protectins [4]. The 
identification of such lipids in human skin is of great interest since it can explain the 
beneficial effect of systemic or topical application of PUFA. Furthemore, nutrigenomics 
applied in tandem with lipidomics and proteomics, during controlled clinical investigations, 
are needed to elucidate the exact role of various anti-inflammatory bioactives showing 
beneficial cutaneous effects.  
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Table 1: Biological effects of selective eicosanoids involved in cutaneous inflammation 
 
Metabolite Biological Effect Cellular Origin 
PGE2 vasodilatation; immunosuppression; 
chemotaxis; proliferation; 
pigmentation 
epidermal keratinocytes; 
dermal fibroblasts 
PGD2 Immunomodulation Langerhans cells; mast cells; 
epidermal keratinocytes 
12S-HETE chemotaxis - leukocyte migration; 
proliferation 
epidermal keratinocytes; 
Langerhans cells; dermal 
fibroblasts 
15S-HETE anti-inflammatory; counteracts 12S-
HETE and LTB4 effects 
epidermal keratinocytes; 
dermal fibroblasts 
13S-HODE anti-inflammatory; anti-proliferatory epidermal keratinocytes; 
dermal fibroblasts 
15S-HETrE anti-inflammatory epidermal keratinocytes; 
dermal fibroblasts 
LTB4 Chemotaxis Infiltrating leukocytes; 
epidermal keratinocytes (low 
levels) 
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Figure legends 
Figure 1: Schematic overview of biosynthetic pathways for the main biologically relevant 
oxygenated products of polyunsaturated fatty acids. acCOX: acetylated COX; AT-RvD1: 
aspirin triggered RvD1.  
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